Johnson & Johnson reported a 96% drop in GAAP net earnings for Q3 due to a one-time legal charge related to talc litigation, but adjusted earnings fell only 7.5%. The company raised its full-year adjusted EPS guidance and maintained a strong dividend, increasing it for the 64th consecutive year. Sales grew 5.9%, driven by oncology and TREMFYA, offsetting declines in other areas. Free cash flow remains robust, supporting the dividend payout, which is about 48% of adjusted EPS, signaling confidence in ongoing financial health despite the headline profit drop.
Johnson & Johnson shares are trading at USD 257.68 on Pluang as of Oct 21, 2026 18:11 WIB, down 0.65% for the day. The stock's dividend yield stands at 2.07%, reflecting its long history of consistent dividend increases. Market participants show a 61% buy interest versus 39% sell in recent Pluang order activity.
With 10-year Treasury yields near 5%, three Dividend Kings—Johnson & Johnson, Procter & Gamble, and Altria—stand out by raising dividends for over 50 consecutive years while maintaining low market volatility (low beta). These companies generate stron...
Johnson & Johnson announced that TREMFYA (guselkumab) maintained or improved fistula remission in adults with Crohn's disease through 48 weeks in the Phase 3 FUZION study. The combined fistula remission rate increased from 28% at Week 24 to 35% at We...
Johnson & Johnson reported a solid quarter with 6% sales growth and strong oncology business expansion, despite a slight miss in MedTech. Analysts maintain a bullish outlook with a 12-month price target of $291.60, implying a 15.6% upside from curren...
